Evropská unie - čeština - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - glecaprevir, pibrentasvir - hepatitida c, chronická - antivirotika pro systémové použití - maviret is indicated for the treatment of chronic hepatitis c virus (hcv) infection in adults and children aged 3 years and older. maviret coated granules is indicated for the treatment of chronic hepatitis c virus (hcv) infection in children 3 years and older.

Evropská unie - čeština - EMA (European Medicines Agency)

accord healthcare s.l.u. - entekavir - hepatitida b, chronická - antivirotika pro systémové použití - entecavir accord is indicated for the treatment of chronic hepatitis b virus (hbv) infection in adults with: , compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (alt) levels and histological evidence of active inflammation and/or fibrosis. , dekompenzovaným onemocněním jater. pro oba kompenzované a dekompenzované onemocnění jater, tato indikace je založena na údajích z klinických studií u pacientů dosud neléčených nukleosidy s hbeag pozitivní a hbeag negativní hbv infekcí. s ohledem na pacienty s hepatitidou b refrakterní lamivudinem. entekavir accord je také indikován k léčbě chronické infekce hbv v nukleosidových naivních pediatrických pacientů od 2 do.

Evropská unie - čeština - EMA (European Medicines Agency)

mylan pharmaceuticals limited - montehydrát entekaviru - Žloutenka typu b - antivirotika pro systémové použití - entecavir mylan is indicated for the treatment of chronic hepatitis b virus (hbv) infection in adults with:compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (alt) levels and histological evidence of active inflammation and/or fibrosis. dekompenzované onemocnění jater. pro oba kompenzované a dekompenzované onemocnění jater, tato indikace je založena na údajích z klinických studií u pacientů dosud neléčených nukleosidy s hbeag pozitivní a hbeag negativní hbv infekcí. s ohledem na pacienty s hepatitidou b refrakterní lamivudinem. entekavir mylan je také indikován k léčbě chronické infekce hbv v nukleosidových naivních pediatrických pacientů od 2 do.

Evropská unie - čeština - EMA (European Medicines Agency)

gilead sciences ireland uc - sofosbuvir, velpatasvir, voxilaprevi - hepatitida c, chronická - antivirotika pro systémové použití - vosevi is indicated for the treatment of chronic hepatitis c virus (hcv) infection in patients aged 12 years and older and weighing at least 30 kg. (viz body 4. 2, 4. 4 a 5.

Evropská unie - čeština - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - odmítnutí štěpu - imunosupresiva - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

krka, d.d., novo mesto, novo mesto array - 15205 kandesartan-cilexetil; 4256 ŽlutÝ oxid ŽelezitÝ; 12990 amlodipin-besilÁt - tableta - 16mg/10mg - kandesartan a amlodipin

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

krka, d.d., novo mesto, novo mesto array - 15205 kandesartan-cilexetil; 12990 amlodipin-besilÁt - tableta - 16mg/5mg - kandesartan a amlodipin

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

krka, d.d., novo mesto, novo mesto array - 15205 kandesartan-cilexetil; 12990 amlodipin-besilÁt - tableta - 8mg/5mg - kandesartan a amlodipin

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

zentiva, k.s., praha array - 15205 kandesartan-cilexetil - tableta - 16mg - kandesartan

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

zentiva, k.s., praha array - 15205 kandesartan-cilexetil - tableta - 32mg - kandesartan